La Defense, France
La Defense, France
SEARCH FILTERS
Time filter
Source Type

News Article | May 8, 2017
Site: www.prnewswire.co.uk

Lamellar is developing a pipeline of novel patent-protected medical devices and pharmaceuticals targeting: Lamellar's pipeline products target conditions that are poorly served by current medications and therefore represent areas of high value unmet medical need. Lamelleye is an approved Class 3 EU Medical Device. Visco-ease is also being developed as a Class 3 EU Medical device. Alec McLean, CEO of Lamellar Biomedical, said: "We are pleased to have closed this Series C fund raising, which will allow us to generate further significant value from our pipeline of potentially groundbreaking LAMELLASOME[TM] based products. We are running clinical trial programmes with Lamelleye and Visco-ease to demonstrate the clear benefits that they can deliver to patients with DED and RIX, respectively. Our First-in-Human study with Muco-ease in CF is expected to start in H2 this year. From these and our other IP, I am also confident that we can build a valuable pipeline of pharmaceutical products based on our unique LAMELLASOME[TM] platform." The funds that have been raised will be used to: Kerry Sharp, Head of the Scottish Investment Bank, said, "Lamellar is a great example of an innovative biotech company using new technology for differentiated product development. Scottish Enterprise works with Lamellar through its account management approach as well as investment from SIB, and we are pleased to continue our support with further investment." Lamellar Biomedical is the only company globally focused on LAMELLASOME[TM] technology (micron-scale lipid vesicles) which has multiple medical applications. Lamellar Biomedical's development pipeline includes a number of patent-protected medical devices and pharmaceuticals targeting Dry Eye Disease, RIX, Cystic Fibrosis and Infection. These are all conditions that are poorly served by current medications and therefore represent areas of high value unmet medical need. LAMELLASOME[TM] technology produces mimetics of human serous lamellar bodies. These regulate the internal interfaces between human tissues as well as the interfaces between tissues and the external environment as in the mouth and lungs. They act biophysically are muco-restorative and have the potential to resolve a broad range of disease states that are associated with dry or sticky mucosal surfaces and topical infection, such as CF. Lamellar Biomedical is based near Glasgow, Scotland. It has been financed by a range of investors including Invesco, Scottish Enterprise, Barwell and TRI Capital. For more information please visit: www.lamellar.com or www.twitter.com/Lamellarbiomed Invesco Perpetual is part of Invesco Ltd, an independent investment management firm - NYSE: IVZ; www.invesco.com. It is the business name of Invesco Fund Managers Limited, a company registered in England and Wales with number 898166 and authorised and regulated by the Financial Conduct Authority and Invesco Asset Management Limited, a company registered in England and Wales with number 949417 and authorised and regulated by the Financial Conduct Authority. The Scottish Investment Bank (SIB) is the investment arm of Scotland's main economic development agency, Scottish Enterprise, operating Scotland-wide in partnership with Highlands and Islands Enterprise. It manages a suite of co- investment funds including the Scottish Co-investment Fund and the Scottish Venture Fund, which are partly funded by the European Regional Development Fund (ERDF), and the Renewable Energy Investment Fund. SIB is also an investor in Epidarex Capital's life sciences fund. SIB's investment funds support Scotland's SME funding market to ensure businesses with growth and export potential have adequate access to growth capital. SIB also provides a team of Financial Readiness specialists to help companies prepare for new investment and access appropriate finance. For further information, please contact: Lamellar Biomedical Dr Alec McLean McLeanA@lamellar.com Tel: +44-(0)-1698-748832 Citigate Dewe Rogerson David Dible/ Pip Batty david.dible@citigatedr.co.uk Tel: +44-(0)20-7282-1022


News Article | May 8, 2017
Site: www.prnewswire.com

Lamellar is developing a pipeline of novel patent-protected medical devices and pharmaceuticals targeting: Lamellar's pipeline products target conditions that are poorly served by current medications and therefore represent areas of high value unmet medical need. Lamelleye is an approved Class 3 EU Medical Device. Visco-ease is also being developed as a Class 3 EU Medical device. Alec McLean, CEO of Lamellar Biomedical, said: "We are pleased to have closed this Series C fund raising, which will allow us to generate further significant value from our pipeline of potentially groundbreaking LAMELLASOME[TM] based products. We are running clinical trial programmes with Lamelleye and Visco-ease to demonstrate the clear benefits that they can deliver to patients with DED and RIX, respectively. Our First-in-Human study with Muco-ease in CF is expected to start in H2 this year. From these and our other IP, I am also confident that we can build a valuable pipeline of pharmaceutical products based on our unique LAMELLASOME[TM] platform." The funds that have been raised will be used to: Kerry Sharp, Head of the Scottish Investment Bank, said, "Lamellar is a great example of an innovative biotech company using new technology for differentiated product development. Scottish Enterprise works with Lamellar through its account management approach as well as investment from SIB, and we are pleased to continue our support with further investment." Lamellar Biomedical is the only company globally focused on LAMELLASOME[TM] technology (micron-scale lipid vesicles) which has multiple medical applications. Lamellar Biomedical's development pipeline includes a number of patent-protected medical devices and pharmaceuticals targeting Dry Eye Disease, RIX, Cystic Fibrosis and Infection. These are all conditions that are poorly served by current medications and therefore represent areas of high value unmet medical need. LAMELLASOME[TM] technology produces mimetics of human serous lamellar bodies. These regulate the internal interfaces between human tissues as well as the interfaces between tissues and the external environment as in the mouth and lungs. They act biophysically are muco-restorative and have the potential to resolve a broad range of disease states that are associated with dry or sticky mucosal surfaces and topical infection, such as CF. Lamellar Biomedical is based near Glasgow, Scotland. It has been financed by a range of investors including Invesco, Scottish Enterprise, Barwell and TRI Capital. For more information please visit: www.lamellar.com or www.twitter.com/Lamellarbiomed Invesco Perpetual is part of Invesco Ltd, an independent investment management firm - NYSE: IVZ; www.invesco.com. It is the business name of Invesco Fund Managers Limited, a company registered in England and Wales with number 898166 and authorised and regulated by the Financial Conduct Authority and Invesco Asset Management Limited, a company registered in England and Wales with number 949417 and authorised and regulated by the Financial Conduct Authority. The Scottish Investment Bank (SIB) is the investment arm of Scotland's main economic development agency, Scottish Enterprise, operating Scotland-wide in partnership with Highlands and Islands Enterprise. It manages a suite of co- investment funds including the Scottish Co-investment Fund and the Scottish Venture Fund, which are partly funded by the European Regional Development Fund (ERDF), and the Renewable Energy Investment Fund. SIB is also an investor in Epidarex Capital's life sciences fund. SIB's investment funds support Scotland's SME funding market to ensure businesses with growth and export potential have adequate access to growth capital. SIB also provides a team of Financial Readiness specialists to help companies prepare for new investment and access appropriate finance. For further information, please contact: Lamellar Biomedical Dr Alec McLean McLeanA@lamellar.com Tel: +44-(0)-1698-748832 Citigate Dewe Rogerson David Dible/ Pip Batty david.dible@citigatedr.co.uk Tel: +44-(0)20-7282-1022


News Article | May 10, 2017
Site: www.eurekalert.org

The University of Plymouth and a collaboration of Cornish and national partners have been awarded £2.7m European funding to improve the use of e-health in Cornwall and the Isles of Scilly The University of Plymouth and a collaboration of Cornish and national partners have been awarded £2.7m European funding to improve the use of e-health in Cornwall and the Isles of Scilly. The project, known as E-health Productivity and Innovation in Cornwall and the Isles of Scilly (EPIC), will involve doctors, nurses, care homes, patients, University academics and small companies in the region to help find the best uses of the internet, apps, and robotics in health and social care. Funded by the European Regional Development Fund (ERDF), EPIC starts this month and runs for three years. Initiatives could include use of video calls to better connect care home residents, development and implementation of apps that support people wanting to make positive behavioural changes, care robots to comfort people with dementia, or even the use of drones to get emergency equipment to rural locations quickly. The collaboration includes Kernow Health CIC, Cornwall Partners in Care, Patients Association, and Creative England, who will work to find technologies that can best help improve services, along with those which are, or can be, produced within Cornwall. The ERDF grant pays for seven project posts, support for small technology companies and a Challenge Fund of £600,000. Grants from this fund will support small and medium-sized enterprises based in Cornwall, offering the potential to create new jobs and support business growth. Project staff will support clinicians, patients, carers and others in bidding for funds from the Challenge Fund to develop and test their ideas. The project will cover all of Cornwall and the Isles of Scilly but have bases in general practices and care homes in St Ives, Redruth, and Liskeard as well as University centres in Truro. Dr Dan Rainbow from Stennack Surgery in St Ives explains why the project will be beneficial for the county: "After 15 years of working with patients in this community, it's obvious that there are gaps in certain areas where I'm sure technology has a role to play in helping to support our patients," he said. "I think technology has had a fairly chequered history in the NHS over the years, and it's exciting to work with people who understand the technology to build up a way of working with our patients from the grass roots upwards to make it work in practice." Project director, Ray Jones, Professor of E-Health at the University of Plymouth, said: "This is a great opportunity for Cornwall to become a centre of excellence in the use of technology for health and social care. It involves people with a range of expertise from across the University, including nursing, medicine, psychology, robotics, business, and public health, working with numerous collaborators across Cornwall and taking a 'bottom up' approach to find or develop technologies that will improve services. "The project involves an international link with universities in Brisbane Australia. At the end of three years we hope to have found new ways in which Cornwall can 'export' its expertise or services to the rest of the UK or beyond while also effectively delivering health and social care for the whole of Cornwall and the Isles of Scilly." A series of webinars are being delivered for people to find out more about the E-health Productivity and Innovation in Cornwall and the Isles of Scilly (EPIC) project. The first, which will give an overview of the project, takes place at 1pm GMT on Wednesday 10 May. To register, visit https:/ . A full list of project webinars can be viewed at https:/


Mallet P.,ERDF Inc | Granstrom P.-O.,EDSO | Hallberg P.,Vattenfall | Lorenz G.,Eurelectric | Mandatova P.,Eurelectric
IEEE Power and Energy Magazine | Year: 2014

The electricity distribution business in Europe is made up of more than 2,400 companies that serve 260 million connected customers, operate 10 million km of power lines, distribute 2,700 TWh a year, and directly employ more than 240,000 people. This is a very diverse business, varying in the number and size of its operational areas, the number of their customers, and the characteristics of the various networks, as well as their ownership structures. Despite this diversity, European distribution system operators (DSOs) generally provide a very high level of reliability and quality of supply to their customers. © 2013 IEEE.


Galli S.,ASSIA Inc | Lys T.,ERDF Inc
China Communications | Year: 2015

In the past decade, several efforts around the world were started with the goal of introducing 'smart metering' capabilities into the power grid. These efforts have spurred renewed interest in the design of next generation Narrowband Power Line Communications (NB-PLC) transceivers. In the past few years, ITU-T and IEEE have standardized a family of next generation OFDM-based NB-PLC transceivers some of which are today being considered for massive deployments in Europe and Asia. This paper addresses the important role that PLC has not only for smart metering but also for many other Smart Grid applications, and also gives an overview of the main differences between these next generation NB-PLC standards. © 2013 IEEE.


Bertrand Y.,Électricité de France | Lauzevis P.,ERDF Inc
IET Conference Publications | Year: 2013

Environmental considerations demand alternatives for the current mineral oils used in many electrical equipment, such as transformers. Because of their excellent biodegradability and non-toxicity, relative to petroleum derived products, the use of the vegetable oils is on the rise as insulating and heat transfer liquid in electrical devices. In addition such natural esters have a favourable lower flammability, but their viscosity and low temperature behaviour is not well suited to applications in cold climate and/or with natural cooling system. That is why a new insulating composition, based on modified vegetable oil, has been developed to present very similar properties to those of the standard insulating mineral oils and to meet the specific needs of current distribution transformers. This article presents the formulation of this low-viscosity ester fluid, and it reports the results of the tests carried out to assess its performance in laboratory and real conditions.


Mouhamad M.,Électricité de France | Lauzevis P.,ERDF Inc
IET Conference Publications | Year: 2013

This paper deals with EDF Research and Development work for ERDF needs in terms of energy efficiency, focused on Amorphous Metal Distribution Transformers (AMDT). The first part is dedicated to evaluate the life-cycle assessment (LCA) of amorphous technology compared to silicon steel technology. It is shown LCA of amorphous units, from raw materials till the recycling, is the most ecofriendly one compared to traditional technology. The second topic is about inrush currents. These currents, measured after re-energization, reach very higher values for amorphous technology than those of conventional technology. The reason for this difference is explained by analyzing magnetic properties of the core and the moment when the transformer is switched in.


Grenard S.,Électricité de France | Devaux O.,Électricité de France | Carre O.,ERDF Inc | Huet O.,Électricité de France
IEEE Power and Energy Magazine | Year: 2011

Distribution networks are facing significant technical constraints and uncertainties. Distribution network operators (DNOs) need to improve the quality of service, integrate high penetrations of distributed generation (or DG, which includes highly variable wind and solar generation), forecast energy flow, and improve efficiency, all while maintaining stable voltage at an acceptable level under all loading and operating conditions. These are major challenges that will be met by developing a network that is often referred to as an active distribution network. This article outlines the progress and plans for moving in this direction at ERDF, the French DNO. © 2011 IEEE.


Razazian K.,Maxim Integrated | Niktash A.,Maxim Integrated | Loginov V.,Maxim Integrated | Leclare J.,Maxim Integrated | And 2 more authors.
ISPLC 2013 - 2013 IEEE 17th International Symposium on Power Line Communications and Its Applications, Proceedings | Year: 2013

G3-PLC is a power line communication standard using OFDM technology for data communication defining both physical and data link layers. The data link layer is derived from IEEE 802.15.4 and Low-Power Wireless Personal Area Network (6LoWPAN) standards. 6LowPAN Ad hoc Distance-vector protocol (LOAD) is used as an efficient routing protocol over varying network topologies and link conditions. Since LOAD was originally developed for wireless networks, several unique enhancements were added to tailor it to power line communications. The enhanced LOAD protocol handles typical issues such as asymmetrical links and ghost nodes. In addition, link repair functionalities are provided and control traffic is reduced. On the other hand, this paper describes how fair channel access is granted to all nodes, providing a sound medium access mechanism which is crucial for a power line communication network. In a second experimental part of the paper, some pressing issues are replicated within a test platform to explore the routing enhancements in a controlled environment. Finally, this paper focuses on the results obtained for a cluster of 132 nodes operating on an actual low voltage grid in Ste Maure de Touraine in the Loire Valley, France. This cluster is part of a 2000 node Advanced Metering Infrastructure (AMI) field trial led by the French Distribution Network Operator (DNO) ERDF. For the first time, results showing enhanced LOAD routing protocol performance within a power line communication AMI deployment are presented. LOAD performs as expected, providing connectivity to all meters installed in a typical residential area. © 2013 IEEE.


Loading ERDF Inc collaborators
Loading ERDF Inc collaborators